The comprehensive criteria encompasses evaluation of debt management, sales growth, earnings-per-share performance, as well as returns on equity
The company reported total income at Rs. 509.8 crore in Q1 FY25 as compared to Rs. 570.3 crore in Q1 FY24
This strong performance was primarily on account of a one-time gain from the strategic collaboration between Biocon Biologics and Eris Lifesciences.
Pharmaceuticals and Consumer Health report higher sales (Fx & portfolio adj.) and lower earnings
The drugmaker's net profit slipped 26 per cent on-year to Rs 143.8 crore
Lonza Bend (US) upgrades capabilities in early phase clinical manufacturing services with the addition of bottling and labeling equipment
The successful completion of the global Phase 3 trials paves the way to obtain marketing approval in the U.S. and EU
Q1 Consolidated operating profit Up 8.3%; revenue grows 7% to Rs 3,349 crore
The revenue for the Q1FY25 came in at Rs 1,085.7 crore, up 16.6 per cent YoY
The acquisition will further strengthen Barentz’ position in India creating a leading life science distribution platform
Subscribe To Our Newsletter & Stay Updated
